Intrapelvic low grade leiomyosarcoma with good prognosis

Soft tissue sarcomas (STS) are rare mesenchymal neoplasms arising from nonepithelial connective tissue origins. Retroperitoneal Soft tissue sarcomas may be primary tumours or metastases especially from the uterus. Here, the authors present a case of intrapelvic leiomyosarcoma treated with hormonotherapy after surgery. A 40-year-old multiparous woman was admitted to the hospital with abdominal pain. Abdominopelvic ultrasound was performed, and an uncircmuscribed mass was seen in the Douglas pouch. At laparotomy, a tumour measuring 7 cm in size, appearing as a sarcoma attached to the sigmoid colon serosa was found. The tumour was positive with H-caldesmon, actin, desmin, oestrogen and progesterone receptors (ER/PR). The patient with a diagnosis of low-grade intrapelvic leiomyosarcoma received adjuvant hormonotherapy after adjuvant radiotherapy. She is doing well without disease recurrence during a two-year follow-up period. Despite contradictory data according to recent limited investigations, the present authors suggest that ER and PR should be routinely quantified in STS by immunohistochemical methods, and it should be kept in mind that hormonotherapy may be a beneficial option.

Intrapelvic leiomyosarcoma; Tumour receptors; Hormonotherapy

[1] Nishimura J., Morii E., Takahashi T., Souma Y., Nakajima K., Doki Y., et al.: ”Abdominal soft tissue sarcoma: a multicenter retrospective study”. Int. J. Clin. Oncol., 2010, 15, 399.

[2] Anaya D.A., Lahat G., Wang X., Xiao L., Pisters P.W., Cormier J.N.: ”Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent”. Ann. Oncol., 2010, 21, 397.

[3] Lewis J.J., Leung D., Woodruff J.M., Brennan M.F.: ”Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution”. Ann. Surg., 1998, 228, 355.

[4] Tseng W., Martinez S.R., Tamurian R.M., Borys D., Canter R.J.: ”Histologic type predicts survival in patients with retroperitoneal soft tissue sarcoma”. J. Surg. Res., 2012, 172, 123.

[5] Verweij J., Baker L.H.: ”Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular abberations”. Eur. J. Cancer, 2010, 46, 863.

[6] Miettinen M., Fetsch J.F.: ”Evaluation of biological potential of smooth muscle tumours”. Histopathology, 2006, 48, 97.

[7] Amant F., Coosemans A., Debiec-Rychter M., Timmerman D., Vergote I.: ”Clinical management of uterine sarcomas”. Lancet Oncol., 2009, 10, 1188.

[8] Zagouri F., Dimopoulos A.M., Fotiou S., Christos V.K., Papadimitriou A.: ”Treatment of early uterine sarcomas: disentangling adjuvant modalities”. World J. Surg. Oncol., 2009, 7, 38.